HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Clinical trials for HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS explained in plain language.
Never miss a new study
Get alerted when new HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS trials appear
Sign up with your email to follow new studies for HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for tough leukemia cases: gentler treatment trial opens for elderly
Disease control Recruiting nowThis study is testing a combination of a targeted cancer drug (inotuzumab ozogamicin) with lower-intensity chemotherapy and immunotherapy for adults with a type of blood cancer called acute lymphoblastic leukemia (ALL). It focuses on patients aged 60 and older, or younger adults …
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 03, 2026 21:41 UTC
-
New Two-Pronged attack tested for Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing a new two-step treatment for people with a high-risk type of aggressive lymphoma who haven't had treatment before. First, patients receive a targeted drug combination designed to seek out and kill cancer cells. This is followed by a standard, but intensive, …
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New Two-Pronged attack on Fast-Growing lymphomas enters patient testing
Disease control Recruiting nowThis study is testing whether adding a new immunotherapy drug, epcoritamab, to a standard chemotherapy regimen (called EPOCH-R) is safe and more effective for treating aggressive B-cell lymphomas. The trial will enroll about 18 adults who have not yet received treatment for their…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Scientists test powerful new drug cocktail in fight against Fast-Growing lymphoma
Disease control Recruiting nowThis early-stage study is testing the safety of adding one or two new targeted drugs to a standard chemotherapy regimen for people with untreated, aggressive B-cell lymphoma. The goal is to see if the new combinations are safe and tolerable for patients. Researchers will enroll a…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New drug targets 'Undruggable' cancer driver in Tough-to-Treat lymphomas
Disease control Recruiting nowThis early-stage trial is testing a new drug called pidnarulex (CX-5461) in adults with aggressive, hard-to-treat B-cell lymphomas that have a specific genetic feature called MYC aberration. The main goals are to find the safest and most effective dose and to see if the drug can …
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Scientists test double punch against Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing whether adding one of two new drugs (tazemetostat or zanubrutinib) to an existing two-drug therapy works better for controlling an aggressive type of blood cancer called large B-cell lymphoma. It is for adults whose cancer has returned or did not respond to …
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC